Introduction {#s0001}
============

Hirschsprung disease (HSCR) is a rare congenital gastrointestinal disease in pediatric surgery. Approximately 80% of HSCR are sporadic and the global incidence is 1/5000. It is reported that males are more predisposed to HSCR than females.[@cit0001] HSCR is characterized by the absence of intestinal submucosal and myometrial ganglion cells, which dues to the event that enteric neural crest-derived cells (ENCDCs) fail to invade, proliferate and migrate to distal colon during embryonic development.[@cit0002],[@cit0003] Severe HSCR will lead to death. Surgery is the only effective treatment. However, postoperative complications such as constipation, fecal incontinence, repeated enteritis and malnutrition continue to bother the survivors. People are actively exploring the intestinal nerve stem cell transplantation technology to improve the prognosis of HSCR, but the progress has been slow.[@cit0004],[@cit0005] Genetic factors play an important role in the pathogenesis and prognosis of HSCR. Any genes affecting cell proliferation, differentiation and migration may cause HSCR.[@cit0006]--[@cit0008] Therefore, expounding the genetic etiologies of HSCR is of great significance for the diagnosis and treatment.

MicroRNAs (miRNAs) belong to non-coding RNAs that are about 22nt long. MiRNAs can specifically recognize the 3ʹUTRs of targeted mRNAs, and subsequently, lead to translation inhibition and mRNA degradation mediated by RNA Induced Silencing Complex (RISC). In this way, miRNAs regulate nearly 60% of human transcripts.[@cit0009] Up to now, many miRNAs such as *miR-150-5p, miR-143, miR-637, miR-483-3p, miR-1324, miR-215, miR-24-1, let-7a, miR-939, miR-770-5p, miR-369-3p, miR-483-5p, miR-206* and *miR-214* have been shown to affect the occurrence and development of HSCR.[@cit0010]--[@cit0021] However, no research has explored the role of *miR-100* to HSCR.

*MiR-100* is a popular cancer-associated molecule involved in the proliferation, differentiation, apoptosis and invasion of tumor cells.[@cit0022] *MiR-100* rs1834306 A\>G polymorphism is located in *pre-miR-100*. In the past, Chang et al and Zhu et al observed that *miR-100* rs1834306 G allele reduced the risk of esophageal squamous cell carcinoma and endometriosis.[@cit0023],[@cit0024] As for colorectal cancer, Boni et al found that the GG/GA genotypes lengthened the time to progression,[@cit0025] while Lampropoulou et al pointed out that a similar effect was performed by the GG genotype.[@cit0026] In addiction, some scholars supported a view that *miR-100* rs1834306 A\>G polymorphism was not associated with tumors.[@cit0027]--[@cit0031]

Recently, some researches indicated that *miR-100* regulated the growth, differentiation and apoptosis of neurons and directly/indirectly affected HSCR-associated pathways.[@cit0008],[@cit0010],[@cit0012],[@cit0016],[@cit0032]-[@cit0034] Considering that rs1834306 may be a potential function site of *miR-100*, we conducted a case--control study to explore the association between *miR-100* rs1834306 A\>G polymorphism and HSCR susceptibility in Southern Chinese population.

Patients and Methods {#s0002}
====================

Study Population {#s0002-s2001}
----------------

During 2000 to 2015, a total of 1470 cases and 1473 controls were collected from Guangzhou Women and Children's Medical Center. There were 240 females (16.33%) and 1230 males (83.67%) in the cases, 458 females (65.65%) and 1015 males (34.35%) in the controls. The frequency distribution of age and gender between cases and controls were significantly different (*P*\<0.001), detailed demographic characteristics can refer to [[Supplemental Table 1](https://www.dovepress.com/get_supplementary_file.php?f=265730.doc)]{.ul}. By histological examination of biopsy specimens, the children with the microscopic characteristics of ganglion cell disappearance and/or submucosal plexus hyperplasia were finally diagnosed with HSCR. The children traveling this hospital at the same period for health examination were recruited as controls. Exclusion criterion: (1) Non-southern Chinese; (2) familiar HSCR or syndromic HSCR; (3) owning the history of other congenital gastrointestinal malformations and endocrine disorders; (4) receiving therapy before blood drawing. According to the range of intestinal lesion, the patients were divided into the groups of short-segment HSCR (SHSCR), long-segment HSCR (LHSCR) and total colonic aganglionosis (TCA).[@cit0035] Our study followed the Helsinki Declaration and was supported by the institutional review board of Guangzhou Women and Children's Medical Center (ethic approve number: 201943800). Written informed consents were obtained from the participants or their guardians.

SNP Selection and Genotyping {#s0002-s2002}
----------------------------

NCBI dbSNP database ([<http://www.ncbi.nlm.nih.gov/projects/SNP>]{.ul}) and SNPinfo ([<https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html>]{.ul}) were used to screen SNPs. Detailed selection criteria were described in the previous article.[@cit0036] Genomic DNA was extracted by the TIANamp Blood DNA Kit and TIANquick FFPE DNA Kit (TianGen Biotech Co., Ltd., Beijing, China). The TaqMan SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA) was used for genotyping.[@cit0037]--[@cit0039] Experiments were conducted in strict accordance with the instructions. No false-positive result was found in negative controls (sterile water) and the repeatable rate of genotyping was 100%.

Statistical Analysis {#s0002-s2003}
--------------------

SAS 9.1 was used for data analysis. Hardy-Weinberg equilibrium (HWE) in controls was estimated by the good-of-fit test. The differences in demographic characteristics between patients and controls were evaluated by the *T*-test and chi-square test. To adjust the confounding effect caused by age and gender, we utilized the unconditional multiple logistic regression model to estimate the association between *miR-100* rs1834306 A\>G polymorphism and HSCR susceptibility. Stratified analysis was performed by HSCR clinical subtypes (SHSCR, LHSCR and TCA). Odds ratios (ORs) and 95% confidence intervals (CIs) were used as statistical indicators. All tests were two-sided. When *P*\<0.05, results were considered statistically significant.

Results {#s0003}
=======

*miR-100* rs1834306 A\>G Polymorphisms and HSCR Susceptibility {#s0003-s2001}
--------------------------------------------------------------

As shown in [Table 1](#t0001){ref-type="table"}, a total of 1398 cases and 1445 controls were successfully genotyped, the genotype frequency of *miR-100* rs1834306 in controls was conformed to HWE (*P*\>0.05). After adjusting for age and gender, we found that G allele and GG genotype significantly increased HSCR susceptibility (GG vs AA: adjusted OR=1.31, 95% CI=1.04--1.64, *P*=0.020; additive model: adjusted OR=1.12, 95% CI=1.01--1.25, *P*=0.041; GG vs AA/AG: adjusted OR=1.30, 95% CI=1.07--1.59, *P*=0.010).Table 1Association Between *miR-100* rs1834306 A\>G Polymorphism and Hirschsprung Disease SusceptibilityGenotypeCases (N=1398)Controls (N=1445)P^a^Crude OR (95% CI)PAdjusted OR (95% CI)^b^P^b^rs1834306 A\>G (HWE=0.126)AA444 (31.76)480 (33.22)1.001.00AG674 (48.21)730 (50.52)1.00 (0.85--1.18)0.9831.01 (0.85--1.20)0.938GG280 (20.03)235 (16.26)**1.29 (1.04--1.60)0.0221.31 (1.04--1.64)0.020**Additive0.046**1.11 (1.002--1.24)0.0461.12 (1.01--1.25)0.041**Dominant954 (68.24)965 (66.78)0.4071.07 (0.91--1.25)0.4071.08 (0.92--1.27)0.359Recessive1118 (79.97)1210 (83.74)0.009**1.29 (1.07--1.56)0.0091.30 (1.07--1.59)0.010**[^2][^3]

Stratification Analysis {#s0003-s2002}
-----------------------

As shown in [Table 2](#t0002){ref-type="table"}, stratified analysis revealed that *miR-100* rs1834306 GG genotype carriers had higher risk to develop HSCR in all clinical subtypes (SHSCR, LHSCR and TCA) when compared with those with AA/AG genotypes. Further, OR was rising with HSCR aggravation (SHSCR: adjusted OR=1.28, 95% CI=1.03--1.59, *P*=0.029; LHSCR: adjusted OR=1.48, 95% CI=1.06--2.07, *P*=0.020; TCA: adjusted OR=2.12, 95% CI=1.22--3.69, *P*=0.008).Table 2Stratification Analysis for the Association Between *miR-100* rs1834306 A\>G and Hirschsprung Disease Susceptibility (by Subtype)Variablesrs1834306 (Cases/Controls)Crude ORPAdjusted OR^a^P^a^AA/AGGG(95% CI)(95% CI)SHSCR797/1210194/235**1.25 (1.02--1.55)0.0351.28 (1.03--1.59)0.029**LHSCR214/121060/235**1.44 (1.05--1.99)0.0241.48 (1.06--2.07)0.020**TCA54/121020/235**1.91 (1.12--3.25)0.0172.12 (1.22--3.69)0.008**[^4][^5]

Discussion {#s0004}
==========

Both enteric nervous system (ENS) and central nervous system (CNS) originate from neural crest, and show high similarities in structure and neurochemistry.[@cit0040] In fact, most HSCR patients with Waardenburg syndromes type 4 or Goldberg-Shprintzen syndrome exhibit some CNS symptoms such as cochlear nerve deafness, seizures or developmental delay.[@cit0041],[@cit0042] Therefore, ENS regulates gastrointestinal function independently of CNS, but we cannot conclude that the developments of ENS and CNS are completely independent. Genetic etiologies that lead to CNS disease may also cause ENS dysfunction.[@cit0040] Recently, Kong et al found that reducing the expression of *miR-100* blocked hydroperoxide-induced apoptosis, promoted the growth and differentiation of retinal ganglion cells, and activated the *TrkB-AKT-ERK* pathway through phosphorylation, suggesting that *miR-100* not only regulated the development of tumor cells, but also that of neurons.[@cit0032] It is noting that the *PI3*/*ATK* and *RAS*/*ERK* pathways have been found to help the *RET* pathway mediate signals which is one of the most important signal pathways implicated in HSCR pathogenesis.[@cit0008]

In addition, *miR-100* was found to block the metastasis of hepatoma cells by inhibiting *ICMT-RAC1* pathway, while *RAC1* was found to activate *PI3K/ATK* pathway.[@cit0033],[@cit0034] Interestingly, Tang et al observed that *RAC1/2* were inactivated after *miR-241* and *Let-7a* inhibiting *ARP2*/*3*, thereby suppressing the migration and proliferation of the 293T and SH-SY5Y cell lines, and proposed that the *mir-241/let-7a-ARP2/3* complex-*RAC* isoforms pathway was a potential pathogenic mechanism for HSCR.[@cit0016]

Above evidences suggested that *miR-100* may take part in the development of HSCR by a complex regulatory network. We hypothesized that increased expression of *miR-100* inhibited *AKT* and *ERK* by the *TrkB-AKT-ERK* or *ICMT-RAC1* pathways to block the signal mediation of the *RET* pathway, besides it can also inhibit the downstream gene of the *mir-241/let-7a-ARP2/3* complex-*RAC* isoforms pathway (*RAC1*) by *ICMT-RAC1* pathway, thus promoting the occurrence and progression of HSCR.

Pri-miRNAs and pre-miRNAs are important precursors of miRNAs. SNPs in the precursors will lead to abnormal expression and secondary structure of miRNAs, which further changes the regulation of miRNAs to targeted mRNAs, eventually cause disease.[@cit0043] In our study, *miR-100* rs1834306 G allele and GG genotype were associated with increased HSCR susceptibility. The same conclusion was observed in all the HSCR subtypes. Furthermore, OR increased gradually with HSCR aggravation, suggesting that GG genotype had a greater genetic pathopoiesis in severe HSCR.

As predicted by SNPinfo, *miR-100* rs1834306 is a transcription factor binding site. In the past, Motawi et al verified that *miR-100* rs1834306 G allele reduced the expression of *miR-100* in hepatitis B.[@cit0044] It seemed to conflict with our prediction that GG genotype would increase *miR-100* expression to promote HSCR by directly/indirectly suppressing the functions of HSCR-associated pathways. The explanations for this contradiction were as follows. First, the same polymorphism may play different roles in diverse diseases. For example, *pre-miR-146a* rs2910164 CC genotype or C allele was found to reduce the expression of *miR-146a* and associated with lower risk to develop prostate cancer and hepatocellular carcinoma.[@cit0045],[@cit0046] However, Shen et al observed that *pre-miR-146a* rs2910164 C allele increased the expression of *miR-146a* and associated with increased susceptibility to earlier familial breast and ovarian cancer.[@cit0047] Therefore, we could not rule out the possibility that rs1834306 G allele or GG genotype upregulated the expression of *miR-100* in HSCR. Second, a research observed that *MIR143HG*, the precursor of *miR-143*, acted as a molecular sponge which could enhance the expression of *RBM24* by competitively binding to *miR-143*.[@cit0011] The similar mechanism may exist between *pre-miR-100* and *miR-100*. We guessed that rs1834306 A\>G polymorphism would lead to down-regulated *miR-100* by decreasing the expression or changing the secondary structure of *pre-miR-100*. Subsequently, the dysfunction of *pre-miR-100* could weaken its combination with *miR-100*, thereby enhancing the inhibition of *mir-100* to HSCR-associated pathways. Finally, the pathogenesis of HSCR and the regulation of *miR-100* are complex, down-regulated *miR-100* may restore a more advantageous pathway that inhibits the proliferation and migration of ENCDCs.[@cit0003] These hypotheses need further verification.

This is the first research about *miR-100* and HSCR. However, there are some limitations in our study. 1. Our study is limited to southern Chinese and the conclusion may not be extrapolated to other populations. 2. Although we have found a significant association between *mir-100* rs1834306 A\>G polymorphism and HSCR susceptibility, we do not conduct any functional experiment to verify this finding.

Conclusion {#s0005}
==========

In conclusion, we suggested that *miR-100* rs1834306 A\>G polymorphism was associated with increased HSCR susceptibility in southern Chinese children. Furthermore, *miR-100* rs1834306 GG genotype had a greater genetic pathopoiesis in severe HSCR.
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